UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000054368
Receipt number R000062095
Scientific Title A study to evaluate the effect of the test food intake on stress
Date of disclosure of the study information 2024/05/10
Last modified on 2025/02/03 09:08:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study to evaluate the effect of the test food intake on stress

Acronym

A study to evaluate the effect of the test food intake on stress

Scientific Title

A study to evaluate the effect of the test food intake on stress

Scientific Title:Acronym

A study to evaluate the effect of the test food intake on stress

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of the test food intake on stress in healthy Japanese men and women

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

State-Trait Anxiety Inventory

Key secondary outcomes

(Secondary outcomes)
Visual Analog Scale, salivary test (cortisol), heart rate variability (LF/HF)
(Safety evaluation)
Vital signs, physical measurements (body weight and BMI), biochemical test, hematology test, urinalysis, adverse events


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Test food intake for 4 weeks
Washout (28 days or more )
Placebo food intake for 4 weeks

Interventions/Control_2

Placebo food intake for 4 weeks
Washout (28 days or more )
Test food intake for 4 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Japanese males and females who are between 20 and 60 years of age at the time of written informed consent.
2.Subjects who are aware of stress on a daily basis.
3.Subjects with the Beck Depression Inventory-II (BDI-II) score of < 20.
4.Subjects who are systolic blood pressure between 101 mmHg and 139 mmHg, and diastolic blood pressure between 61 mmHg and 89 mmHg.
5.Subjects who have a regular or part-time job.
6.Subjects who are fully explained the purpose and details of the study, have ability to consent, are volunteering to participate in the study with a full understanding of the explanation, and have consented to participate in the study in writing.

Key exclusion criteria

1.Subjects receiving medication or outpatient treatment for a serious disease.
2.Subjects receiving exercise or diet therapy under the supervision of a physician.
3.Subjects who may develop an allergy to the ingredient of the test food (rosemary) or aspirin.
4.Subjects with current or previous history of drug dependence or alcohol dependence.
5.Subjects who are currently seeing a doctor for the treatment of a psychiatric disorder (e.g., depression) and/or sleep disorder (e.g., insomnia, sleep apnea syndrome) or have previous history of a psychiatric disorder.
6.Subjects who have extremely irregular life rhythms due to night work, shift work, etc.
7.Subjects whose eating, sleeping, and other habits are extremely irregular.
8.Subjects who are having a very unbalanced diet.
9.Heavy users of alcohol (the mean consumption of pure alcohol is 60 g/day or more) or excessive smokers (21 cigarettes/day or more).
10.Subjects with current or previous history of a brain disease, malignancy, immunological disease, diabetes mellitus, hepatic disease (hepatitis), renal disease, cardiac disease, thyroid disease, adrenal disease, metabolic disease, or other serious diseases.
11.Subjects who use or are unable to stop using health foods, supplements (e.g., GABA, rosemary, caffeine, and theanine), and drugs that may affect stress.
12.Subjects who regularly drink energy drinks.
13.Subjects who anticipate a major change or stressful situation in their home or working environment (e.g., job change, move, marriage) from one month before screening to study completion.
14.Subjects who participated in another clinical study/research within 3 months before the date of informed consent or who plan to participate in another clinical study/research during the study period.
15.Subjects who donated more than 200 mL of whole blood, plasma, or platelets within 1 month before the date of informed consent or 400 mL within 3 months before the date of informed consent.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Satoshi
Middle name
Last name Fukumitsu

Organization

NIPPN CORPORATION

Division name

Innovation Center, Central Research Laboratory

Zip code

243-0041

Address

5-1-3 Midorigaoka Atsugi Kanagawa 243-0041, Japan

TEL

046-222-6963

Email

sfukumitsu@nippn.co.jp


Public contact

Name of contact person

1st name Hiroyuki
Middle name
Last name Miyazawa

Organization

HUMA R&D CORP

Division name

Clinical Development Department

Zip code

108-0023

Address

NAKANO SPRING Bld 5F, 4-11-17 Shibaura, Minato-ku, Tokyo 108-0023 Japan

TEL

03-3431-1260

Homepage URL


Email

rd@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

NIPPN CORPORATION

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

AMC Shinjuku Clinic Ethics Committee

Address

5F,SIL Shinjuku-building ,2-46-3,Kabukicho,Shinju-ku,Tokyo,160-0021,Japan

Tel

03-6709-6071

Email

amcshinjuku@amc-clinic.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 05 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2024 Year 04 Month 04 Day

Date of IRB

2024 Year 04 Month 12 Day

Anticipated trial start date

2024 Year 05 Month 13 Day

Last follow-up date

2024 Year 09 Month 27 Day

Date of closure to data entry

2024 Year 10 Month 21 Day

Date trial data considered complete

2024 Year 10 Month 24 Day

Date analysis concluded

2025 Year 01 Month 28 Day


Other

Other related information

(Exclusion criteria continued)
16.Subjects who are currently pregnant or lactating, may become pregnant during the study period, or are planning to become pregnant during the study period.
17.Subjects who have difficulty complying with recording of each survey form.
18.Subjects whose laboratory test values or measurements at screening indicate their ineligibility to participate in the study.
19.Other Subjects who are considered ineligible for participation in the study by the investigator.


Management information

Registered date

2024 Year 05 Month 10 Day

Last modified on

2025 Year 02 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000062095